Clinical Scorecard: Differential Analysis of Inflammatory and Metabolic Biomarkers in Neurocritical Conditions: A Focus on Myasthenia Gravis and Guillain–Barré Syndrome
At a Glance
Category
Detail
Condition
Myasthenia Gravis and Guillain–Barré Syndrome
Key Mechanisms
Immune-mediated disruption of the peripheral nervous system and neuromuscular junction.
Target Population
Hospitalized patients with Myasthenia Gravis and Guillain–Barré Syndrome requiring immunotherapy.
Care Setting
Neurocritical care
Key Highlights
Mechanical ventilation used in 10.5% of patients, correlating with neurological severity.
In MG, NLR and SII are strong indicators of severe disease and negative outcomes.
LDH-related metrics, especially LAR, correlate with disease severity in MG.
In GBS, clinical outcomes are primarily influenced by neurological impairment.
Post-treatment increases in transaminases modestly correlate with severe disease in GBS.
Guideline-Based Recommendations
Diagnosis
Diagnosis of MG confirmed through clinical criteria and serological assessments.
Management
Treatment with intravenous immunoglobulin and/or plasma exchange.
Monitoring & Follow-up
Monitor neurological severity and respiratory function closely.
Risks
Risk of respiratory failure necessitating mechanical ventilation.
Patient & Prescribing Data
162 individuals (88 with MG, 74 with GBS).
Aggressive immunotherapy is often required for both conditions.
Clinical Best Practices
Utilize inflammatory biomarkers for risk stratification in MG.
Assess neurological severity as a key predictor of outcomes in both MG and GBS.
Consider LDH and LAR as potential indicators of metabolic stress in MG.
